B cells

[Frontiers in Immunology] Researchers used a novel interleukin 35 reporter model to understand which signaling pathways are important for immunosuppressive properties in B cells.

[Nature Chemical Biology] To overcome these problems, scientists developed a novel class of CAR-T cells engineered to express an enzyme that activated a systemically administered small-molecule prodrug in situ at a tumor site.

[Journal of Experimental & Clinical Cancer Research] The authors assessed the efficacy and safety of B cell maturation antigen (BCMA) and CD38 bispecific CAR-T cells in refractory multiple myeloma patients.

[Clinical Cancer Research] Researchers performed targeted next-generation sequencing, immunohistochemistry for MYC, BCL2, and FN1, and fluorescent multiplex immunohistochemistry for microenvironmental markers in a large cohort of diffuse large B cell lymphoma.

[Blood Advances] The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific T cell engager molecule, for treatment of pediatric relapsed/refractory B cell precursor acute lymphoblastic leukemia were examined in an open-label, single-arm, expanded access study (RIALTO).

[Science Translational Medicine] Investigators evaluated the B cell subsets, Breg cell function, and the effect of B cell depletion therapy on these cells in patients with neuromyelitis optica spectrum disorder.